RGNX
REGENXBIO Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.92
−3.04%Aug 25, 2026, 00:00 UTC
A.N. "Jerry" Karabelas resigned as a director of REGENXBIO Inc., effective August 25, 2026.
Aug 25, 2026, 00:00 UTC
Jean Bennett resigned as a director of REGENXBIO Inc., effective August 25, 2026.
Aug 25, 2026, 00:00 UTC
REGENXBIO Inc. appointed Gregory Ciongoli as a Class II director, effective August 25, 2026, and he will serve on the Audit Committee and the Nominating and Corporate Governance Committee.
Aug 24, 2026, 11:25 UTC
The U.S. Food and Drug Administration placed a clinical hold on Regenxbio's experimental gene therapy for Hunter syndrome after spinal scans found abnormalities in five study participants.
Aug 6, 2026, 11:05 UTC
REGENXBIO reaffirmed the path forward for RGX-121 for Hunter syndrome with the FDA during a productive July Type A meeting, with resubmission on track for Q3 2026.
Aug 6, 2026, 11:05 UTC
REGENXBIO announced that its BLA submission for RGX-202 for Duchenne muscular dystrophy is on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027.
Source:Aug 6, 2026, 11:05 UTC
REGENXBIO announced that topline data from pivotal subretinal wet AMD studies, ATMOSPHERE and ASCENT, are expected in Q4 2026.
Source:Aug 6, 2026, 11:05 UTC
REGENXBIO raised over $200 million in new capital in July 2026, extending its cash runway into Q4 2027.
Source:Aug 6, 2026, 11:05 UTC
REGENXBIO reported its second quarter 2026 financial results and operational highlights.
Aug 6, 2026, 00:00 UTC
REGENXBIO Inc. received a $100 million milestone payment from AbbVie for the first patient dosing in the NAAVIGATE trial.
Source:Jul 20, 2026, 14:45 UTC
REGENXBIO Inc. announced long-term clinical trial results for its experimental gene therapy surabgene lomparvovec (sura-vec, ABBV-RGX-314) targeting wet age-related macular degeneration and diabetic retinopathy.
Source:Jul 16, 2026, 20:26 UTC
REGENXBIO Inc. announced a proposed public offering of $100 million of its common stock.
Source:Jun 29, 2026, 11:05 UTC
REGENXBIO dosed the first patient in the Phase IIb/III NAAVIGATE trial of surabgene lomparvovec for diabetic retinopathy.
Source:Jun 24, 2026, 11:55 UTC
The FDA agreed to reconsider a Hunter syndrome gene therapy that it had previously rejected.
Source:Jun 24, 2026, 11:55 UTC
Regenxbio will submit its Duchenne muscular dystrophy gene therapy for accelerated approval to the FDA.
Source:Jun 24, 2026, 11:05 UTC
REGENXBIO completed dosing in the confirmatory study of RGX-202, a gene therapy for Duchenne muscular dystrophy, marking completion of the registrational development program.
Source:Jun 23, 2026, 15:51 UTC
Regenxbio plans to resubmit the Biologics License Application (BLA) for Navsunli for MPS II after FDA alignment on next steps.
Source:Jun 22, 2026, 11:30 UTC
REGENXBIO aligned with the FDA on the path forward for the NAVSUNLI BLA resubmission for accelerated approval of the gene therapy for MPS II.